
Keywords: ریتوکسیماب; AAV; ANCA-associated vasculitis; ANCA; antineutrophil cytoplasm antibody; CYP; cyclophosphamide; EULAR; European League Against Rheumatism; GPA; granulomatosis with polyangiitis; MPO; myeloperoxidase; PR3; proteinase 3; RTX; rituximab;